middle.news
Clarity’s Cu-SARTATE Doubles Lesion Detection in NETs, Phase III Trial Next
10:00am on Thursday 5th of June, 2025 AEST
•
Healthcare
Read Story
Clarity’s Cu-SARTATE Doubles Lesion Detection in NETs, Phase III Trial Next
10:00am on Thursday 5th of June, 2025 AEST
Key Points
Cu-SARTATE detected nearly twice as many NET lesions as Ga-DOTATATE
High lesion-level sensitivity of 93.4% to 95.6% confirmed for Cu-SARTATE
Well tolerated with no serious adverse events reported
Phase III registrational trial planned with FDA guidance
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clarity Pharmaceuticals (ASX:CU6)
OPEN ARTICLE